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 Abstract  
  As part of efforts to improve study design, the use of outcome measures in randomized 
controlled trials (RCTs) in traumatic brain injury (TBI) is receiving increasing attention. This 
review aimed to assess how clinical outcome assessments (COAs) have been used and 
reported in RCTs in adult TBI. Systematic literature searches were conducted to identify 
medium to large (n ≥ 100) acute and post-acute TBI trials published since 2000. Data were 
extracted independently by two reviewers using a set of structured templates. Items from the 
Consolidated Standards of Reporting Trials (CONSORT) 2010 Statement and CONSORT 
patient-reported outcomes (PRO) extension were used to evaluate reporting quality of COAs. 
Glasgow Outcome Scale/Extended (GOS/GOSE) data were extracted using a checklist 
developed specifically for the review. A total of 126 separate COAs were identified in 58 
studies. The findings demonstrate heterogeneity in the use of TBI outcomes, limiting 
comparisons and meta-analyses of RCT findings. The GOS/GOSE was included in 39 studies, 
but implemented in a variety of ways, which may not be equivalent. Multidimensional 
outcomes were used in 30 studies, and these were relatively more common in rehabilitation 
settings. The use of PROs was limited, especially in acute study settings. Quality of reporting 
was variable, and key information concerning COAs was often omitted, making it difficult to 
know how precisely outcomes were assessed. Consistency across studies would be increased 
and future meta-analyses facilitated by (a) using common data elements recommendations 
for TBI outcomes and (b) following CONSORT guidelines when publishing RCTs. 
 
Key words: clinical outcome assessments; systematic review; randomized controlled trials; 
traumatic brain injury; multidimensional outcomes  
 
 Introduction 
  There is increasing awareness of the importance of clinical outcome assessments (COAs) in 
evaluating health care interventions.1 Furthermore, in clinical research, there is recent 
emphasis both on standardizing data collection, and on multidimensional outcome 
assessment including the patient’s perspective.2 In recognition of the central role of outcomes 
in clinical studies, the US Food and Drugs Administration (FDA) has implemented a 
qualification program for COAs.3 The terminology developed to describe COAs is outlined in 
a Task Force report by the International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR)1 and summarized in Table 1. The ISPOR report recommends that COAs 
should be targeted to clinical treatments; that is, in randomized controlled trials (RCTs), 
selected COAs should be specifically chosen to determine whether there is a treatment 
benefit on the intended aspect of patient functioning or feeling (i.e., the concept of interest). 
The COAs selected should also be of clinical value to patients, in that they should measure 
meaningful aspects of health that affect daily living.1  
 
  In traumatic brain injury (TBI) research, there is currently a drive towards standardizing data 
collection using a common set of measures which can be used to provide a multidimensional 
description of outcome.4-9 At its simplest, multidimensional assessment means going beyond 
using a single endpoint to include two or more outcome domains. Multiple outcome domains 
are relevant to TBI, including global functional outcome, cognition, health-related quality of 
life, TBI symptoms, and psychological status.4, 7, 8, 10 Current common data elements (CDEs) 
recommendations for TBI outcomes include clinician-reported outcomes (clinROs), patient-
reported outcomes (PROs), and performance outcomes (PerfOs).4 The CDE outcomes for TBI 
comprise one core measure of global functioning, the GOSE, as well as a variety of basic and 
 supplemental outcome measures, which can be used across all TBI study types.4 Use of 
common outcomes promotes meta-analyses and provides a potential opportunity for pooling 
data for secondary analysis; it is particularly desirable in medium to large scale studies where 
the information collected may form a valuable legacy for use in the future.11 
 
  Measures of global functional outcome, such as the Glasgow Outcome Scale (GOS) and its 
extended version, the Glasgow Outcome Scale-Extended (GOSE), have often been used alone 
as the primary endpoint in trials of treatments for moderate to severe TBI.12-15 However, the 
GOS/GOSE has been criticized for being insensitive to subtle changes in functioning.7, 8, 12, 14-
18 In addition, the GOS/GOSE may be collected in a variety of different ways, potentially 
yielding results that are not comparable. There is currently no systematic overview of how 
COAs have been used in clinical trials in TBI. Furthermore, the extent to which previous TBI 
trials have used a multidimensional set of outcomes, or a single measure of global functional 
outcome such as the GOS/GOSE, is unclear, and warrants investigation.  
 
  Transparency and completeness in the reporting of RCTs is essential to inform clinical 
decision-making. However, the reporting quality of COAs in TBI trials has not specifically been 
evaluated. A review by Lu et al (2015) used the Consolidated Standards of Reporting Trials 
(CONSORT) statement19 to evaluate whether the reporting quality of methodological 
characteristics in adult TBI trials has improved over time.20 Although reporting has improved 
over time in line with developments in the CONSORT reporting guidelines, Lu et al (2015) 
concluded that there remains a need for increased transparency in the reporting of clinical 
trial methodologies in adult TBI. Incomplete reporting makes it difficult to assess the 
methodological rigour of RCTs and hinders ‘risk of bias’ assessments. Sub-optimal reporting 
 of outcomes in clinical trials is also problematic because it interferes with the interpretation 
of findings, and ultimately, limits their ability to inform clinical practice guidelines.  
 
  The current systematic review focuses on medium to large scale RCTs in adults with TBI 
published from 2000 onwards. The review had two main objectives: (1) To document patterns 
of use of COAs; and (2) To evaluate quality of reporting of COAs using COA-specific items from 
the CONSORT 2010 checklist, CONSORT PRO extension, and other COA-relevant reporting 
criteria. 
 
Methods 
Search Strategy 
 Systematic online literature searches were conducted between October 2015 and May 2017 
to identify RCTs investigating the effectiveness of acute and post-acute treatments, 
interventions, and management strategies in adult TBI. The following online databases were 
searched: PubMed, CINAHL Complete, and PsychInfo. PubMed and CINAHL Complete were 
searched using the MeSH terms “brain injuries” (exact subject) AND “randomised controlled 
trial/randomized controlled trial" (title/abstract). PsychInfo was searched using the terms 
"traumatic brain injury" (DE subjects [exact]) AND "randomized controlled trial/randomised 
controlled trial" (AB Abstract). Two clinical trials registries, www.clinicaltrials.gov and the 
Cochrane Central Register of Controlled Trials (CENTRAL), were searched using the MeSH 
term "brain injuries" and condition "traumatic brain injury." A hand search was conducted by 
searching the reference lists of two recent systematic reviews of RCTs in TBI.13, 20 If a single 
study had more than one publication, linked papers were included in the review and 
evaluated as one publication.  
   The references retrieved from the database search were imported to the Covidence 
system,21 where the titles and abstracts were screened independently by two authors 
according to the following inclusion and exclusion criteria:   
 
Inclusion Criteria  
1. Clinical trials investigating acute or post-acute treatments, interventions, or 
management strategies for TBI   
2. Adult participants (predominantly aged 16 and over) 
3. Articles published from 2000 to the present 
4. Articles published in academic journals 
5. Articles published in English  
6. Medium scale (n = 100-500) and large scale studies (n>500)  
 
Exclusion Criteria  
1. Small scale studies (n< 100)  
2. Feasibility studies, pilot studies, study protocols, progress reports 
3. Retrospective analyses of previously published RCTs    
 
Data Extraction 
  Data extraction was carried out independently by two authors. Quality was ensured by 
randomly selecting 5 studies, piloting data extraction for these studies, and refining the 
process where necessary before proceeding. Further quality control measures were 
implemented by completing data extraction in sets of 10, and by discussing and resolving any 
discrepancies that occurred, until data extraction was complete.    
 Study characteristics  
  The following information relating to general study characteristics was extracted: sample 
size (i.e., number randomized); study size (medium/large); participant age (overall 
mean/median age, age range); TBI severity (mild/moderate/severe); setting (acute/post-
acute); participation sites (single/multicentre); intervention characteristics/type of study; 
treatment benefit; treatment mechanism; hypothesis; primary COA(s); secondary COA(s); 
time point of primary interest; time point of secondary interest; follow-up rate. 
 
Risk of Bias   
  Selection bias has been found to influence RCT outcomes and is a central measure of study 
quality. Therefore, risk of selection bias was assessed using two key domains from the 
Cochrane Risk of Bias Tool: random sequence generation and allocation concealment. Risk of 
bias was categorized as high, low, or unclear (if insufficient information was provided), in line 
with Cochrane Collaboration definitions.22 This approach is consistent with that used in a 
recent scoping review of RCTs in moderate-to-severe TBI.13  
 
Patterns of use of COAs 
  Frequency counts were made to identify: (1) How many COAs were used; (2) Which 
assessments were used most often; (3) How many studies used multidimensional outcomes 
(i.e., use of two or more measures covering different assessment domains as defined in the 
CDEs); and (4) Which type of COA was used most commonly in each setting (i.e., clinRO, PRO, 
perfO, obsRO), both for primary outcomes and for outcomes that were used in any capacity 
(including primary outcomes, secondary outcomes, and combined outcomes). Combined 
 outcomes consist of two or more component outcome measures which are combined into a 
single endpoint,23, 24 or analyzed jointly using a global test.25, 26 
 
Quality of reporting of COAs 
  A checklist was developed to assess the reporting quality of COAs. The checklist was based 
on COA-relevant items from the CONSORT PRO extension,27 CONSORT 2010 Statement,19 and 
other additional COA-relevant reporting criteria. The CONSORT PRO extension provides 
guidance on how to describe patient-reported outcomes (PRO). However, as this review is 
concerned with COAs more generally, items from the CONSORT checklists were evaluated for 
all four types of COA (i.e., clinRO, PRO, perfO, obsRO). Some additional COA-relevant items 
were added, and some of the CONSORT checklist items were expanded for the purposes of 
this review (see Table 3 in Results for details).  
 
Glasgow Outcome Scale  
  Patterns of use and quality of reporting were evaluated for the GOS/GOSE using a checklist 
which was developed specifically for this review. The checklist was used to assess the 
following items: (1) Whether the GOS/GOSE was used as a primary outcome, secondary 
outcome, or not at all; (2) Method of assessment (i.e., clinician assessed, structured interview, 
or postal questionnaire); (3) Whether extracranial injuries were included in the rating; (4) 
Method of dealing with severe pre-existing disability; (5) Method of contact for assessment 
(i.e., face-to-face, telephone, or postal); (6) Source of information (i.e., patient, proxy 
respondent, or other sources); (7) Method of assigning final rating (i.e., researcher rating or 
central review); (8) Whether the assessor was trained; (9) Whether scores were 
 dichotomized; and (10) Whether ordinal analysis methods were used (including analysis of 
ranked data, sliding dichotomy, and proportional odds ratio methods).  
 
Statistical analysis 
  The results were summarized descriptively using frequencies (i.e. number of studies) and 
percentages (i.e. proportion of studies) for each of the items of interest. The data were 
analyzed using Microsoft Excel®.  
 
Results  
Study selection process 
  The online literature search yielded a total of 1861 references. The hand search revealed an 
additional 6 articles which met the inclusion criteria for the review. After removing duplicates, 
a total of 1137 separate references were left to be screened. Of these references, 1025 were 
excluded. The remaining 113 full-text articles were assessed for eligibility. Fifty-five of the full-
text articles were excluded, leaving a total of 58 studies to be included in the review. The 
study selection process is detailed in Figure 1.       
 
Study characteristics  
  The general characteristics of the studies are presented in Supplementary Table 1. Key study 
characteristics are summarised in Table 2. Most of the studies were conducted in acute 
settings (n = 38), and most were medium sized (n = 51). Almost half of the studies were 
conducted with patients with severe TBI (n = 27), most studies were multicentre (n = 38), and 
most had follow-up rates of 90% or better (n = 41). Six months post-injury was the most 
popular time point of primary interest (n = 31).  
 Risk of Bias  
  Risk of selection bias for each study is presented in Supplementary Table 1. Figure 2 shows 
that random sequence generation was rated as low risk of bias in 42 studies (27 acute; 15 
post-acute), unclear risk of bias in 15 studies (11 acute; 4 post-acute), and high risk of bias in 
1 post-acute study. Allocation concealment was rated as low risk of bias in 39 studies (25 
acute; 14 post-acute), unclear risk of bias in 18 studies (12 acute; 6 post-acute), and high risk 
of bias in 1 acute study.   
 
Patterns of use of COAs 
  A total of 126 separate COAs were identified within the 58 studies. The full list of COAs by 
type, study setting, and frequency of use are listed in Supplementary Table 2. Twenty-six 
(21%) of the COAs were used exclusively in acute studies, 82 (65%) were used exclusively in 
post-acute studies, and 18 (14%) were used across both study settings. Figure 3 shows that 
the ten most commonly used COAs were the GOS, GOSE, Disability Rating Scale (DSR), Trail 
Making Test Parts A & B (TMT A&B), SF-36, Controlled Oral Word Association Test (COWAT), 
Functional Independence Measure (FIM), Selective Reminding Test (SRT), Galveston 
Orientation and Amnesia Test (GOAT), and Rivermead Post-Concussion Questionnaire (RPQ). 
Of these 10 COAs, the 3 most frequently used were the GOS (21 studies), GOSE (21 studies), 
and DRS (12 studies). The GOS was used exclusively in the acute studies, whereas the GOSE 
was used in 16 of the acute studies and 5 of the post-acute studies. The DRS was used in 8 of 
the acute studies and 4 of the post-acute studies.  
 
  A total of 30 studies used multidimensional outcomes (12 acute studies, 18 post-acute 
studies. Twenty-four of the studies with multidimensional outcomes reported individual 
 outcome measures; 5 studies used a composite multidimensional outcome; and 1 study used 
a global test to create a multidimensional outcome, i.e., the TBI Clinical Trials Network Core 
Battery.25, 26 
 
  The COAs were classified according to whether they were clinROs, PROs, perfOs, or obsROs. 
Supplementary Table 3 shows the number and proportion of studies that used each type of 
COA, both as a primary outcome, and in any capacity (i.e., as a primary outcome, secondary 
outcome, or as part of a composite outcome). Overall, clinROs were the most popular type of 
COA: they were used mostly in acute settings, and accounted for 54% of acute study primary 
outcomes. PROs were used rarely in acute settings, but they were used more commonly in 
post-acute settings. Overall, a total of 20 studies used more than one type of COA (9 acute 
studies; 11 post-acute studies). For primary outcomes, 10 studies used more than one type 
of COA (3 acute studies; 7 post-acute studies).   
 
Quality of reporting of COAs  
  Reporting quality of COAs was assessed across the 58 studies. The number and percentage 
of studies that met each quality criterion is reported in Table 3. Each article was assessed 
according to whether the individual quality criteria were met. For cases where the 
information was unclear, or partially met, the criterion was rated as unmet. Reporting of 
primary and secondary outcome measures was assessed separately for checklist item 4. The 
numbers and percentages for each criterion are adjusted accordingly for sub-groups (see 
Table 3Legend).  
 
   Reporting of COAs was variable across the quality criteria. The checklist items that were 
reported most completely include: (2a) Treatment benefit defined (95% of all studies); (4i) 
Timing of follow up for primary outcomes stated (98% of all studies); (7) Baseline COA data 
provided, if collected (100% of the 20 applicable studies); (8) Numbers analysed for COA 
results stated (98% of all studies); (10c) Implications for clinical practice discussed (100% of 
all studies); (11) COA data interpreted in relation to clinical outcomes, including survival data, 
where relevant (100% of all studies). Reporting varied between acute and post-acute studies, 
and primary outcomes were generally reported more completely than secondary outcomes, 
especially in the post-acute studies. Reporting quality varied across criteria for checklist item 
4: Overall, the proportion of studies meeting the criteria ranged from 6% for ‘Number of 
assessors stated for secondary outcomes,’ to 98% for ‘Timing of follow-up for primary 
outcomes stated.’ The following checklist items were least complete: (3) COA hypothesis 
stated and relevant domains defined, if applicable (57% of all studies); (9a) Effect size 
reported (53% of all studies); (9aii) For binary outcomes, absolute effect size stated (28% of 
applicable studies); (9b) Confidence intervals (or other measures of precision) reported (57% 
of all studies); (10a) COA-specific limitations discussed (36% of all studies); and (10b) 
Implications for generalizability discussed (41% of all studies). 
 
Glasgow Outcome Scale 
  The GOS/GOSE was the most commonly used COA overall. The scale was used in 39 of the 
58 studies (67%). Figure 4 shows how often the scale was used as a baseline measure, primary 
outcome, secondary outcome, or as part of a composite outcome. The scale was used in its 
original 5-point format (GOS) in 21 studies (GOS guided interview = 20 studies; GOS postal 
questionnaire = 1 study), and in its extended format (GOSE) in 21 studies (GOSE questionnaire 
 = 3 studies; GOSE structured interview = 18 studies). It was used as a primary outcome in 29 
studies (GOS = 19 studies, GOSE structured interview = 8 studies, GOSE questionnaire = 1 
study). It was used as a secondary outcome in 7 studies (GOS = 3 studies, GOSE structured 
interview = 3 studies, GOSE questionnaire = 1 study): 3 of these studies used the GOS as a 
primary outcome as well as the GOSE questionnaire as a secondary outcome. The GOSE 
structured interview was used as part of a composite in 5 studies, and as a baseline measure 
in 2 studies.   
 
  Table 4 displays the patterns of use and completeness of reporting in the 39 studies that 
used the GOS or GOSE. Clinician assessed/guided interviews were used in 46% of the studies 
(17 acute studies; 1 post-acute studies), while structured interviews were used in 44% of the 
studies (13 acute studies; 4 post-acute studies), and postal questionnaires were the primary 
assessment in 10% of the studies (4 acute studies; no post-acute studies). None of the articles 
stated whether extracranial injuries were included in the ratings, and 90% (35 studies) did not 
state the methods used to deal with pre-existing severe disability. Around half of the articles 
did not state the primary method of contact (18 acute studies; 2 post acute studies), and 64% 
(23 acute studies; 2 post-acute studies) did not report the source of information/respondent. 
Final ratings were assigned by the researcher in 87% of the studies (29 acute studies; 5 post-
acute studies), and by central review in 13% of the studies (all 5 were acute studies). Most 
articles (69%) did not state whether the outcome assessor was trained (22 acute studies; 5 
post-acute studies). GOS/GOSE scores were dichotomized in 59% of the studies (all 23 were 
acute studies), while ordinal analysis methods were used in 38% of the studies (12 acute 
studies; 3 post-acute studies).   
 
 Discussion  
  This review aimed to evaluate how clinical outcome assessments (COAs) have been used and 
reported in RCTs in adult TBI from 2000 onwards. A total of 58 clinical trials were assessed 
according to key study characteristics, risk of selection bias, patterns of use of COAs, and 
reporting quality of COAs. The included articles demonstrate that the majority of RCTs that fit 
criteria were medium in size (i.e., n=100-500), and most studies investigated acute hospital 
treatments for moderate and severe TBI.  
 
  A wide range of COAs were used across the included studies, and there were differences in 
the use of outcomes depending on the setting in which the RCT was conducted. A greater 
range of COAs were used in the post-acute studies, and there was little commonality between 
acute and post-acute settings. The most popular COAs were measures of global functional 
outcome, including the GOS, GOSE, and DRS. However, most of the COAs were used 
infrequently (i.e., in 1 to 3 studies). Considerable variability therefore exists in the use of 
outcome measures in TBI trials, especially in post-acute settings, making it challenging to link 
acute and post-acute studies.5 The frequent use of the GOS/GOSE in the reviewed studies is 
not surprising and is consistent with the subsequent CDE recommendations for TBI.4 
Nevertheless, the GOS/GOSE has not been used universally in TBI clinical trials. The 
introduction of outcome CDEs for TBI should help to reduce variability in the assessments 
used in RCTs. However, it is notable that since first proposed,6 the number of outcome CDEs 
has grown, and compartmentalisation of different areas of TBI assessment remains. 
 
  As multidimensional outcome assessment is increasingly important in the field of TBI, the 
GOS/GOSE is now recognised to be insufficient on its own as an outcome measure.7, 8, 16 
 Despite this, around half of the reviewed studies used a single outcome: most of these were 
acute studies, and the GOS/GOSE was the most frequently used endpoint. Around half of the 
studies used multidimensional outcomes: most of the post-acute studies used 
multidimensional outcomes, whereas a minority of the acute studies used multidimensional 
outcomes. Most studies with multidimensional outcomes used separate COAs to measure 
multiple outcome domains, and composite multidimensional outcomes were relatively 
uncommon. While ClinROs such as the GOS/GOSE were common in the acute studies, PROs 
were used rarely in these studies. Regulators have encouraged the use of PROs,28 but these 
assessments have not proven popular in TBI, perhaps because they are not as closely linked 
to the neural substrate as functional outcome measures.25 The findings from the review 
demonstrate that multidimensional outcomes are not used universally in TBI trials. Moreover, 
multidimensional outcomes are more commonly used in clinical trials in rehabilitation 
settings, perhaps due to treatments that are more clearly targeted to behavioural change and 
designed to tap into multiple outcome domains.    
   
  The overall reporting quality of COAs was variable across the reviewed studies, suggesting 
that reporting is sub-optimal in TBI trials. Most articles provided a sufficient background and 
rationale for the outcomes. Furthermore, the criteria relating to timing of follow-ups, 
participant numbers, baseline outcomes data, implications for clinical practice, and 
interpretation of clinical outcomes, were consistently well met across the studies. Overall, the 
most incompletely reported aspects included COA hypotheses, effect sizes and confidence 
intervals, COA-specific limitations, and implications for generalizability. Some key differences 
were identified between the acute and post-acute studies. Although acute studies were 
relatively better at explaining treatment mechanisms, more attention was paid to outcomes 
 in rehabilitation settings (i.e., hypotheses were stated more clearly, primary outcomes were 
defined more fully, and COA-specific limitations and implications for generalizability were 
more likely to be discussed). In the acute studies, there was often a lack of rationale for the 
choice of endpoint, possibly because pharmaceutical trials in acute TBI tend to be motivated 
by animal studies and there is a substantial gap between the behavioural measures typically 
used in laboratory work and the COAs used in human studies (i.e., GOS/GOSE). In future 
clinical trials, investigators should therefore ensure that outcomes are well defined and 
carefully selected to capture treatment benefit on specific aspects of the patient’s functioning 
or feeling.1  
 
  Despite the wide use of the GOS/GOSE, certain aspects were reported particularly poorly 
across the studies. None of the included articles reported whether extracranial injuries were 
included in the GOS/GOSE ratings, and most studies provided no information about the 
method used to deal with pre-existing severe disability. Around two thirds of the articles did 
not state who the respondent was (i.e., the TBI patient or a proxy informant), or whether the 
outcome assessor was trained. Furthermore, around half of the articles did not provide 
sufficient information about the primary method of contact for GOS/GOSE assessments (i.e., 
face-to-face contact, telephone contact, postal questionnaire). In contrast, reporting of 
GOS/GOSE scoring and analysis methods was relatively complete, the method of assigning 
final ratings was clear in all of the articles, and it was apparent in most studies if the GOS/GOSE 
scores were dichotomized or if ordinal analysis methods were used.   
 
  Transparent reporting of how the GOS/GOSE is used and analysed is important in RCTs 
because variability in methods of data collection and scoring may influence study findings. 
 Important issues to consider when assigning outcome on the GOS/GOSE include the influence 
of extracranial injury, pre-existing disability, and source of information (i.e., TBI patient or 
proxy informant).29 Inter-rater variability is another important issue when assigning outcome 
and interviewer training is required to achieve high levels of agreement between assessors.30 
Extracranial concomitant injury can have an effect on functional outcome.31, 32 However, the 
original description of the structured interview for the GOSE noted that the scale did not 
distinguish the effects of brain injury from the effects of concomitant injuries to other parts 
of the body:  investigators needed to decide whether to include or exclude extracranial 
injuries in the overall rating of disability.29 Both approaches have been used in RCTs, with 
some trials including extracranial injuries in the assessment (e.g. the Dexanabinol Trial),33 and 
others excluding the influence of non-brain injuries (e.g. PROTECT III).34 This represents a 
substantial difference in the way that outcome assessments have been conducted, and one 
that should be documented in future trial reports.  
 
  Previous studies suggest that the GOSE postal questionnaire and structured telephone 
interview can be used as a reliable means of assigning functional outcome in the absence of 
face-to-face contact.35, 36 Nevertheless, robust comparisons between these different methods 
of GOSE data collection have not been made. The GOSE questionnaire is increasingly used in 
TBI trials.37-40 However, as impaired self-awareness can affect TBI patients’ ability to provide 
an accurate self-report,41 the GOSE questionnaire may not be appropriate in all contexts. 
Disagreements between GOSE questionnaires and GOSE interviews may occur if postal 
questionnaires are self-completed by patients who lack insight into their own functional 
limitations,36 and investigators should take this into consideration when deciding which 
method of GOSE data collection to use in future TBI studies.    
   This review provides information about the patterns of use and reporting quality of 
outcomes in adult TBI trials published from the year 2000 onwards. However, it is important 
to note that the review has limitations. As changes in the use and reporting of COAs were not 
examined over time, the impact of the CDE recommendations for common outcome 
measures in TBI,4, 6 and the CONSORT guidelines for RCT reporting,19, 27 on clinical trials in TBI 
is unknown. Furthermore, as the review was restricted to medium and large scale RCTs (i.e., 
n≥100), the findings may have differed if smaller scale RCTs had been included. The inclusion 
criteria may have been biased against post-acute studies, as these are often smaller in scale 
than acute TBI studies.  
 
Conclusion 
  This review demonstrates shortcomings in the use of COAs in adult TBI trials to date and 
highlights the issue of incomplete reporting of outcomes in these studies. Heterogeneity in 
the use of clinical trial endpoints is problematic because it interferes with meta-analyses of 
trial findings and makes it difficult to pool data for secondary analyses. Incomplete reporting 
of outcomes is also problematic because it limits the transparency of RCT findings and 
compromises their clinical applicability. To address the issues raised in this review, future 
studies in adult TBI should follow CDE outcomes recommendations to increase consistency in 
the use of COAs and facilitate future meta-analyses.4 Future RCTs in adult TBI should also 
adhere to CONSORT guidelines to ensure transparency in the reporting of outcomes and 
contribute to the development of clinical guidelines.19, 27 As the GOSE is currently 
recommended as the core COA within multidimensional outcome assessments in TBI,4, 7, 8 
further research into how it is used is now warranted and its associations with other outcome 
domains should be ascertained.   
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 Table 1: Types of COA  
Type of COA Definition*  
Clinician-reported outcome 
(ClinRO) 
A type of COA in which a member of the investigator team 
is the rater. The investigator’s professional training is 
relied upon to judge what rating or score will be reported 
Patient-reported outcome 
(PRO) 
A COA in which the report comes directly from the patient. 
The patients’ responses to questions about their health 
condition are recorded without amendment or 
interpretation by anyone else. 
Performance Outcome 
(PerfO) 
A COA in which the patient is assessed by performing a 
defined task that is quantified in a specified way. Although 
a member of the investigator team may administer the 
PerfO task and monitor the patient’s performance, the 
investigator does not apply judgment to quantify the 
performance. 
Observer-reported outcome 
(ObsRO) 
A COA in which observations can be made, appraised, and 
recorded by a person other than the patient who does not 
require specialized professional training. The rating is 
nonetheless influenced by the perspective of the observer. 
*Definitions taken from Walton et al (2015) 
 
 
 
 
 Table 2: Key study characteristics  
 Number (%) of RCTs 
Acute  
(n = 38) 
Post-acute 
(n = 20) 
Overall 
(n = 58) 
Sample size   
      100-500 (medium) 31 (81%) 20 (100%) 51 (88%) 
      >500 (large) 7 (19%) 0 (0%) 7 (12%) 
TBI Severity (GCS score)  
      13-15 (mild) 1 (2%) 6 (30%) 7 (12%) 
      9-12 (moderate) 0 (0%) 0 (0%) 0 (0%) 
      3-8 (severe) 25 (66%) 2 (10%) 27 (46%) 
      3-15 (all severities) 3 (8%) 4 (20%)  7 (12%) 
      9-15 (mild/moderate) 0 (0%) 1 (5%) 1 (2%) 
      3-12 (moderate/severe) 9 (24%) 7 (35%) 16 (28%) 
Participation Centres   
      Single Centre 14 (37%) 6 (30%) 20 (34%) 
      Multicentre 24 (63%) 14 (70%) 38 (66%) 
Time point of primary interest  
      <6-months post-injury 5 (13%) 3 (15%) 8 (14%) 
      6-months post-injury 29 (77%) 2 (10%) 31 (53%) 
      1-year post-injury 0 (0%) 4 (20%) 4 (7%) 
      >1-year post-injury 1 (2%) 8 (40%) 9 (16%) 
      Other 3 (8%) 3 (15%) 6 (10%) 
 Follow-up rate  
      ≥90% 32 (84%) 9 (45%) 41 (71%) 
      80-89% 2 (6%) 7 (35%) 9 (16%) 
      70-79% 1 (2%) 2 (10%)  3 (5%) 
      <70% 1 (2%) 2 (10%) 3 (5%) 
       Not stated 2 (6%) 0 (0%) 2 (3%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3: Quality of reporting of COAs 
 
Quality Criterion 
Number (% of RCTs) meeting criterion 
Acute 
(n = 38) 
Post-acute 
(n=20) 
All studies 
(n = 58) 
1. COA identified in abstract as a primary/ secondary outcome 28 (74%) 17 (85%) 45 (78%) 
2. Background and rationale for COA provided 
a. Treatment benefit defined* 
b. Explanation of treatment mechanism* 
 
35 (92%) 
34 (89%) 
 
20 (100%) 
12 (60%) 
 
55 (95%) 
46 (79%) 
3. COA hypothesis stated and relevant domains defined, if 
applicable 
 
16 (42%) 
 
17 (85%) 
 
33 (57%) 
4. Completely defined pre-specified ◊primary outcomes  
a. Validity & reliability described or source citation given 
b. Who assessed outcomes stated 
c. Number of assessors stated* 
d. Whether assessors were blind is clear 
e. Native language with validated translation* 
f. Methods of contact stated, e.g., telephone/postal/face-
to-face 
g. Respondent stated (e.g., patient/proxy, other sources) 
h. Whether respondent was blind stated* 
i. Timing of follow-up stated 
 
25 (71%) 
24 (69%) 
4 (11%) 
29 (83%) 
13 (37%) 
17 (49%) 
 
15 (43%) 
16 (46%) 
35 (100%) 
 
18 (90%) 
18 (90%) 
5 (25%) 
18 (90%) 
16 (80%) 
16 (80%) 
 
19 (95%) 
11 (55%) 
19 (95%) 
 
43 (78%) 
42 (76%) 
9 (16%) 
47 (85%) 
29 (53%) 
33 (60%) 
 
34 (62%) 
27 (49%) 
54 (98%) 
4. Completely defined pre-specified ◊◊secondary outcomes 
a. Validity & reliability described or source citation given 
b. Who assessed outcomes stated 
c. Number of assessors stated* 
d. Whether assessors were blind is clear 
e. Native language with validated translation* 
 
10 (63%) 
11 (69%) 
1 (6%) 
16 (100%) 
7 (44%) 
 
11 (65%) 
10 (59%) 
1 (6%) 
12 (71%) 
10 (59%) 
 
21 (64%) 
21 (64%) 
2 (6%) 
28 (48%) 
17 (52%) 
 f. Methods of contact stated, e.g., telephone/postal/face-
to-face 
g. Respondent stated (e.g., patient/proxy, other sources) 
h. Whether respondent was blind stated* 
i. Timing of follow-up stated 
6 (38%) 
 
8 (50%) 
11 (69%) 
16 (100%) 
9 (53%) 
 
11 (65%) 
9 (53%) 
12 (71%) 
15 (45%) 
 
19 (58%) 
20 (61%) 
28 (85%) 
5. Statistical approaches for dealing with missing data are 
explicitly stated 
 
26 (68%) 
 
19 (95%) 
 
45 (78%) 
6. Number of participants at baseline and subsequent time 
points given 
 
30 (79%) 
 
19 (95%) 
 
49 (85%) 
7.  ∆Baseline COA data provided, if collected 3 (100%) 17 (100%) 20 (100%) 
8. Numbers analysed for COA results stated 38 (100%) 19 (95%) 57 (98%) 
9. For each primary and secondary outcome, results for each 
group provided 
a. Effect size reported 
i. For binary outcomes, ∆∆relative effect size stated 
ii. For binary outcomes, ∆∆absolute effect size stated 
b.      Confidence intervals (or other measures of                
precision) reported 
 
 
22 (58%) 
19 (79%) 
7 (29%) 
27 (71%) 
 
 
9 (45%) 
1 (100%) 
0 (0%) 
6 (30%) 
 
 
31 (53%) 
20 (80%) 
7 (28%) 
33 (57%) 
10a.   COA-specific limitations discussed 
10b.   Implications for generalizability discussed  
10c.   Implications for clinical practice discussed 
6 (16%) 
10 (26%) 
38 (100%) 
15 (75%) 
14 (70%) 
20 (100%) 
21 (36%) 
24 (41%) 
58 (100%) 
11. COA data interpreted in relation to clinical outcomes, 
including survival data, where relevant 
 
38 (100%) 
 
20 (100%) 
 
58 (100%) 
   
*Expanded items developed for this review are marked with asterisks 
 ◊Applicable in 55 studies (35 acute studies; 20 post-acute studies)  
◊◊Applicable in 33 studies (16 acute studies; 17 post-acute studies) 
 ∆Applicable in 20 studies (3 acute studies; 17 post-acute studies) 
∆∆Applicable in 25 studies (24 acute studies; 1 post-acute studies)       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 4: GOS/GOSE patterns of use and completeness of reporting  
 Acute 
(34 studies) 
Post-acute 
(5 studies) 
Totals* 
(39 studies) 
Method of assessment 
a. Clinician assessed/guided interview 
b. Structured interview 
c. Questionnaire 
 
17 
13 
4 
 
1 
4 
0 
 
18 (46%) 
17 (44%) 
4 (10%) 
 Extracranial injuries included in rating 
a. Not stated 
 
34 
 
5 
 
39 (100%) 
Method of dealing with pre-existing severe 
disability  
a. Patients with pre-existing SD excluded 
b. Not stated 
 
 
4 
30 
 
 
0 
5 
 
 
4 (10%) 
35 (90%) 
Primary method of contact 
a. Face-to-face interview 
b. Telephone interview 
c. Postal questionnaire 
d. Face-to-face clinical assessment 
e. Face-to-face or telephone interview 
f. Postal questionnaire, telephone 
interview, or face-to-face interview 
g. Not stated 
 
3 
6 
3 
1 
2 
1 
 
18 
 
0 
1 
0 
0 
2 
0 
 
2 
 
3 (8%) 
 7 (17%) 
3 (8%) 
1 (3%) 
4 (10%) 
1 (3%) 
 
20 (51%) 
Source of information/respondent  
a. Patient alone 
b. Proxy alone 
c. Patient and proxy 
d. Patient or proxy 
f. Not stated 
 
2 
0 
1 
8 
23 
 
3 
0 
0 
0 
2 
 
5 (13%) 
0 (0%) 
1 (3%) 
8 (20%) 
25 (64%) 
 Method of assigning final rating 
a. Researcher 
b. Central review 
 
29 
5 
 
5 
0 
 
 34 (87%) 
5 (13%) 
Outcome assessor is trained 
a. Yes 
b. Not stated 
 
12 
22 
 
0 
5 
 
12 (31%) 
27 (69%) 
Scores are dichotomized 
a. Yes 
b. No 
c. Not stated 
 
23 
11 
0 
 
0 
4 
1 
 
23 (59%) 
15 (38%) 
1 (3%) 
Ordinal analysis methods used  
a. Yes 
b. No 
 
12 
22 
 
3 
2 
 
15 (38%) 
24 (62%) 
 
*Data are number (%) of the 39 studies that used the GOS/GOSE 
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Figure 4: GOS/GOSE patterns of use for the original 5-point 
GOS rating, postal questionnaires for GOS and GOSE, and the 
GOSE structured interview 
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Figure 3: Most commonly used COAs       
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 Supplementary Table 1: General Study Characteristics and Risk of Selection Bias  
General Study Characteristics Risk of 
Selection Bias 
Acute drug studies (neuroprotection) 
Treatment/ 
Intervention 
n Mean/ median* 
age, (range) 
TBI 
Severity 
Study 
Setting 
Primary outcome(s) 
(time point)  
Secondary outcome(s) or other 
outcome measures  
 
Follow-up 
rate  
RSG AC 
Wilsonii injecta 1 120 33.6 (18-60) severe acute 
single centre 
Glasgow Outcome Scale (GOS) 
(6 months) 
n/a not stated U U 
CRASH 
Corticosteroid 
Study 2, 3 
10,008 not stated 
(adults) 
all acute 
multicentre 
GOS (6 months) n/a 97% U L 
CRASH-2 
Tranexamic Acid  
4 
270 36.5 (adults) all acute 
multicentre 
modified Oxford Handicap Scale 
(mOHS) (6 months) 
n/a 100% L L 
Intensive Insulin 
Therapy 5  
188 53 (range not 
stated) 
severe acute 
multicentre 
GOS (90 days after ICU 
admission) 
mortality, neurological outcome 
at different time points  
100% L L 
Mannitol  
6 
178 29 (adults)  severe acute 
single centre 
GOS (6 months) n/a 100% L U 
Mannitol 
7 
141 30 (adults) severe acute 
single centre 
GOS (6 months) n/a 100% L U 
 Valproate  
8 
279 36.2 (14 and 
over) 
moderate/
severe 
acute 
single centre 
Neuropsychological battery 
including Finger Tapping Test, 
Namewriting Test, Seashore 
Rhythm Test, Trail Making Test 
(TMT) Part A & B, Stroop Color 
Word Tests Parts 1 &2, 
Wechsler Memory Scale – 
Revised (WMS-R): Attention 
and Concentration Index, 
Logical Memory and Visual 
Reproduction, Selective 
Reminding Test  (SRT)(recall 
and delayed recall), Kimura 
Memory for Designs Test, 
Wechsler Adult Intelligence 
Scale (WAIS) Verbal Intelligence 
Quotient (VIQ) and 
Performance Intelligence 
Quotient (PIQ), Controlled Oral 
Word Association Test (COWAT)   
(1/6/12 months) 
n/a 1m = 87%                
6m = 53%              
12 m = 38% 
L L 
Erythropoietin 9  159 42.3 (15-71) severe acute 
single centre 
GOS (3 months after treatment. 
Patients treated within 6 hours 
of injury) 
n/a 92% U U 
 Pharmos 
dexanabinol trial 10 
861 32.5* (16-65) severe acute 
multicentre 
Glasgow Outcome Scale - 
Extended (GOSE) (6 months) 
Barthel Index, SF-36 98% L L 
Erythropoietin, 
EPO-TBI trial 11 
606 30.5* (16-83) moderate/
severe 
acute 
multicentre 
GOSE (6 months) n/a 98% L L 
Erythropoietin 12 200 30 (range not 
stated) 
severe acute 
multicentre 
GOS (GOSE) (6 months) Disability Rating Scale (DRS)  91% U L 
BRAIN TRIAL of 
Bradykinin 
antagonist 
Anatibant 13 
228 36.4 (16-65)  moderate/
severe 
acute 
multicentre 
Serious Adverse Events (15 days 
after injury) 
GCS, Disability Rating Scale 
(DRS), mOHS 
96% L L 
SYNAPSE Trial of 
progesterone 14 
1195 34.5*(16-70)  severe acute 
multicentre 
GOS (6 months) GOSE, SF-36 99% L L 
Magnesium 15 499 34.4 (14 and 
over)  
moderate/
severe 
acute 
single centre 
Composite comprising 39 
individual measures, including 
mortality, seizures, functional 
measures (i.e., functional status 
examination (FSE), GOSE, Sf-
36), and cognitive tests (i.e., 
Weschsler Abbreviated Scale of 
Intelligence (WASI) Full Scale 
IQ, WAIS III – Processing Speed 
Index, SRT, Paced Auditory 
Serial Additional test (PASAT), 
TMT A&B, Finger Tapping Test, 
n/a 93% 
neuropsych. 
tests  = 72% 
L L 
 Grooved Pegboard Test, 
COWAT, Stroop Test (1&2), 
Kimura Memory for Designs 
Test, Galveston Orientation and 
Amnesia Test (GOAT) 
(6 months)  
Progesterone, 
PROTECT III trial 16 
882 35* (adults)  moderate/
severe 
acute 
multicentre 
GOSE (6 months) DRS 94% L L 
Intensive insulin 
therapy 17 
240 45.5 (adults)  severe acute 
single centre 
Mortality (6 months) GOS 97% U L 
Traxoprodil 18 404 31.3 (16-70)  severe acute 
multicentre 
GOS (6 months) DRS, Cognitive Abilities 
Screening Instrument (CASI), 
GOSE 
93% L U 
Tranexamic acid 19 238 34.5 (16 and 
over)  
moderate/
severe 
acute 
single centre 
Intracranial haemorrhage  
(at hospital discharge) 
GOS 100% L L 
Citicoline, COBRIT 
trial 20 
1213 not stated (18-
70)  
moderate/
severe 
acute 
multicentre 
TBI clinical trials network 
battery (i.e., TMT A&B, GOSE, 
COWAT, California Verbal 
Learning Test (CVLT), WAIS III 
Processing Speed Index, and 
Digit Span, Stroop test (1&2)) 
(90 days) 
 
 
n/a 82% L L 
  
 
Hypothermia trials 
Study  n Mean/ median* 
age, (range) 
TBI 
Severity 
Study 
Setting 
Primary outcome  
(time point)  
Secondary outcomes 
 
Follow-up 
rate  
RSG AC 
Hypothermia, 
Eurotherm Study 21 
387 37 (legal age of 
consent and 
over) 
moderate/
severe 
acute 
multicentre 
GOSE (6 months) modified 
Oxford Handicap Scale (mOHS) 
97% L L 
Hypothermia 22 392 31.5 (16-65) severe acute 
multicentre 
GOS (6 months) Neurobehavioural Rating Scale-
Revised, DRS, GOAT, SRT, Rey-
Osterrieth Complex Figure Test, 
Symbol Digit Modalities Test, 
TMT Part B, COWAT, Grooved 
Pegboard Test 
96% U U 
Hypothermia 23 232 28.5 (16 - 45) severe acute 
multicentre 
GOS (6 months) DRS 92% L L 
Hypothermia 24 215 32.9 (18-45) severe acute 
multicentre 
GOS (6 months) n/a 100% U U 
Hypothermia,  
B-HYPO study 25 
148 39 (15-69) severe acute 
multicentre 
GOS (6 months) n/a 99% L L 
 Physiology of 
hypothermia 26 
148 27.3 (18-64)  severe acute 
single centre 
Physiology & GOS (1-7 years) GOS unclear U U 
Hypothermia 27 396 42.5 (15-65) severe acute 
single centre 
GOS (6 months) n/a 
 
 
 
100% U U 
Surgical trials 
Study  n Mean/ median* 
age, (range) 
TBI 
Severity 
Study 
Setting 
Primary outcome  
(time point)  
Secondary outcomes 
 
Follow-up 
rate  
RSG AC 
Decompressive 
Craniectomy 
(DECRA) 28 
155 24.2* (15-59) severe acute 
multicentre 
GOSE (6 months) n/a 100% L L 
STICH Surgical trial 
29, 30 
170 48 (16-83) all acute 
multicentre 
Postal GOSE (6 months) Rankin Scale, EuroQol (EQ-5D) 99% L H 
Decompressive 
Craniectomy 31 
408 33.6 (10-65) severe acute 
multicentre 
GOSE (6 months) GOSE, SF-36 98% L L 
Standard vs limited 
Craniectomy  
32 
486 44.5 (14-70)  severe acute 
multicentre 
GOS (6 months) n/a 100% L L 
Surgical trial of 
Decompression  
33  
182 36.8 (14-72) severe acute 
single centre 
GOS (5-60  months) n/a 91% U U 
 Surgical trial of 
Craniectomy 34 
230 45.6 (range not 
stated)  
severe acute 
single centre 
GOS (6 months) n/a 100% U U 
Other acute studies (pre-hospital intubation, osmotic therapy, technology/monitoring, bed rest) 
Study  n Mean/ median* 
age, (range) 
TBI 
Severity 
Study 
Setting 
Primary outcome  
(time point)  
Secondary outcomes 
 
Follow-up 
rate  
RSG AC 
Pre-hospital 
intubation 35 
312 40.7 (15 and 
over) 
severe acute 
multicentre 
GOSE (6 months) GOSE dichotomised  96% L L 
Acute osmotic 
therapy. Early 
hypertonic fluids 36 
1331 38.9 (15 and 
over) 
severe acute 
multicentre 
GOSE (6 months) DRS 85% L L 
Acute osmotic 
therapy. 
Pre-hospital 
hypertonic saline 37 
229 37.5 (18 and 
over) 
severe acute 
multicentre 
GOSE (6 months)  Functional Independence 
Measure (FIM), Rancho Los 
Amigos Scale  
99% L L 
Technology/ 
monitoring- ICP 
Monitoring 38 
324 29* (13 and 
over) 
severe acute 
multicentre 
Composite with 21 components 
including survival, GOAT, GOSE, 
DRS, Mini Mental Status Exam 
(MMSE), Spanish Verbal 
Learning Test, Brief VisuoSpatial 
Memory Test, WAIS III Digit 
Symbol and Symbol Search, 
Grooved Pegboard Test, TMT 
Part A, Color Trails 1&2, 
n/a 92% L L 
 COWAT, Category Fluency - 
Animals and Actions, PASAT   
(6 months) 
Technology/monito
ring - CPP display 39 
157 37 (16 and over)  moderate/
severe 
acute 
single centre 
GOSE and FSE (6 months) n/a 100% L L 
Bed rest for mTBI  
40 
107 37 (older than 
15) 
mild acute 
single centre 
16 post-traumatic complaints 
including cognitive, vegetative, 
dysthymic, and physical 
symptoms, SF-36  
(2 weeks/3 months/6 months) 
n/a 74% L U 
Post-acute drug studies 
Study  n Mean/ median* 
age, (range) 
TBI 
Severity 
Study 
Setting 
Primary outcome  
(time point)  
Secondary outcomes 
 
Follow-up 
rate  
RSG AC 
Amantadine 41 184 36.4 (16-65)  severe post-acute 
multicentre 
DRS (4 weeks after treatment. 
Patients recruited within 4-16 
weeks of injury) 
Coma Recovery Scale-Revised 
(CRS-R) 
98% L L 
Amantadine 42 168 39.2 (16-75)  moderate/
severe 
post-acute 
multicentre 
Neuropsychiatric Inventory 
(NPI-I) most problematic item  
(28 days after treatment. 
Patients recruited at least 6 
months after injury) 
NPI most aberrant item, NPI 
distress score, Clinical Global 
Impressions (CGI) 
94% L L 
 Armodafanil 43 117 31.3 (18-65) mild/ 
moderate 
post-acute 
multicentre 
multiple sleep latency test 
(MSLT), Clinical Global 
Impressions of Change (CGI-C)  
(2, 4, 8, 12 weeks. Patients 
recruited 1-10 years post-
injury) 
Epworth Sleepiness Scale (ESS), 
MSLT, Clinical Global 
Impression of Severity of Illness 
(CGI-S), Clinical Global 
Impression of change (CGI-C) 
73% to 98%  U U 
Rivastigmine 44 157 37.1 (18-50)  all post-acute 
multicentre 
Cambridge Neuropsychological 
Test Automated Battery 
(CANTAB) Rapid Visual 
Information Processing (RVP), 
Hopkins Verbal Learning Test 
(HVLT) (12 weeks. Patients 
recruited at least 1 year after 
injury) 
CANTAB (RVP, Spatial Working 
Memory (SWM), Paired 
Associates Learning (PAL) & 
Reaction Time (RT)), HVLT, 
COWAT, WAIS-III Digit Span & 
Letter-Number Sequencing, 
TMT A&B, Neurobehavioural 
Functioning Inventory (NFI), 
Beck Depression Inventory II 
(BDI-II), Deiner Satisfaction with 
Life scale, CGI-C 
85% L L 
Rivastigmine 45 102 45.5 (18 and 
over) 
all post-acute 
single centre 
Symptom Checklist 90 (SCL-90), 
Deiner Satisfaction with Life 
Scale, Cognispeed tests (i.e., 
simple reaction time, ten-
choice reaction time, 
subtraction and vigilance tests). 
(Baseline, end of period 1, after 
n/a 68% L L 
 wash-out, after 2nd period. 
Patients recruited at least 1 
year after injury) 
 
 
 
 
 
 
 
Post-acute rehabilitation/counselling studies 
Study  n Mean/ 
median* age, 
(range) 
TBI Severity Study 
Setting 
Primary outcome  
(time point)  
Secondary outcomes 
 
Follow-up 
rate  
RSG AC 
Mindfulness-based 
cognitive therapy 46 
105 46.5 (18 and 
over) 
all post-acute 
multicentre 
Beck Depression Inventory-II 
(Post 10-week intervention. 
Time since TBI not reported) 
PHQ-9, SCL-90-R, Philadelphia 
Mindfulness Scale (PHLMS), 
Toronto Mindfulness Scale 
(TMS) 
72%   
Telephone 
counselling 47 
171 36 (18-70) moderate/ 
severe 
post-acute 
single centre 
Composite including FIM, DRS, 
Community Integration 
Questionnaire (CIQ), NFI, FSE, 
GOSE, SF-36, Brief Symptom 
Inventory (BSI), EuroQol EQ-5D, 
Individual measures and 
composites of measures in a 
common outcome domain 
92% L L 
 Modified Perceived Quality of 
Life (PQOL) (1 year) 
Telephone 
counselling 48 
366 32.5 (16 and 
over) 
mild post-acute 
single centre 
Two composites for post-
traumatic symptoms (Head 
Injury Symptom Checklist and 
12 functional areas) and 
general health (SF-12, PQOL, 
PHQ, major role, and 
community integration) (6 
months) 
n/a 86%   
Telephone 
counselling 49 
433 39 (16 and 
over) 
moderate/ 
severe 
post-acute 
multicentre 
Composite including FIM, DRS,  
Participation with Recombined 
Tools - Objective (PART-O), 
GOSE, EuroQol EQ-5D, PQOL, 
Sf-12, BSI-18 (1 year) 
functional composite (FIM, DRS, 
GOSE, PART-O, EuroQol EQ-5D), 
community participation, 
wellbeing, and vocational 
measures 
1 year: 82% 
2 year: 81% 
L L 
Self-advocacy 
intervention 50 
257 47.9 (18 and 
over) 
moderate/ 
severe 
post-acute 
multicentre 
Advocacy Behaviour Rating 
Scale (ABRS) (at least 1 year 
since injury)  
n/a 84% U U 
Early intervention 
for mTBI  
51 
395 33 (16-60) mild post-acute 
single centre 
Post-Concussion Symptoms 
Questionnaire (PCSQ), Life 
Satisfaction Questionnaire 
(LiSat-11), CIQ, SF-36 (1 year) 
Interest Checklist, Role 
Checklist, Job Satisfaction 
Checklist 
90% L L 
 CBT for depression  
52  
100 45.8 (18 and 
over) 
Complicated 
mild to 
severe 
post-acute 
multicentre 
Hamilton Depression Rating 
Scale (HAMD-17) & patient-
reported Symptom Checklist-20 
(SCL-20) (16 weeks after 
recruitment to study. Patients 
recruited within 10 years of 
injury) 
PHQ-9, MINI International 
Neuropsychiatric Interview, 
Environmental Reward 
Observation Scale (EROS), 
Automatic Thoughts 
Questionnaire (ATQ), 
Dysfunctional Attitudes Scale 
(DAS), Patient Global 
Impression (PGI), Satisfaction 
with Depression Care, Working 
Alliance Inventory - Short Form, 
SF-36, Head Injury Symptom 
Checklist 
100% L L 
Multidisciplinary 
rehab for mTBI 53 
191 32 (16-60) mild post-acute 
multicentre 
Rivermead Post-Concussion 
Questionnaire (RPQ), 
Rivermead Follow-up 
Questionnaire (RFQ), General 
Health Questionnaire (GHQ), 
neurocognitive battery (Stroop 
Test, Symbol-Digit Modalities 
Test, Paced Visual Serial 
Addition Task, Simple Reaction 
Time, Choice Reaction Time, 
HVLT, WAIS III Vocabulary, 
n/a 89% U U 
 WAIS III Letter-Number 
Sequencing, WAIS III Matrix-
Reasoning (6 months) 
Early rehab for 
mTBI 54 
173 39.4 (15-70) mild post-acute 
multicentre 
RPQ, Hospital Anxiety and 
Depression Scale (HADS), (3 
months) 
n/a 83% L L 
Community-based 
rehab 55 
110 34.5 (16-65) severe post-acute 
single centre 
Barthel Index, Brain Injury 
Community Rehabilitation 
Outcome-39 (BICRO-39) 
(18-40 months after allocation. 
No limit on duration since 
injury) 
FIM, Functional Assessment 
Measure (FAM), HADS  
85% L L 
Cognitive rehab 56 120 25.5 (range 
not stated)  
moderate/ 
severe 
post-acute 
single centre 
Return to work and fitness for 
duty  
(12 months after treatment. 
Patients recruited within 3 
months of injury) 
MMSE, SRT, Trahan Continuous 
Visual Memory Test 
(TCVMT),PASAT, Wisconsin 
Card Sorting Test (WCST),WMS-
R General Memory, Auditory 
Consonant Trigrams, Halsted-
Reitan Neuropsychological 
Impairment Index, Katz 
Adjustment Scale  
100% L L 
 Brief alcohol 
intervention 57 
202 35.8 (18 and 
over) 
moderate/ 
severe 
post-acute 
multicentre 
Alcohol Expectancy 
Questionnaire III, Readiness to 
Change Questionnaire (3 
months following treatment) 
 59% U L 
Comparison of two 
rehab approaches 
58 
360 32.5* (18 and 
over)  
moderate/ 
severe 
post-acute 
multicentre 
Functional independence, 
return to work or school (1 year 
post-treatment. Patients 
recruited within 6 months of 
injury) 
CVLT, WMS-R, Semantic 
Fluency, Lexical Fluency, TMT 
Part B, WCST, FIM, DRS, Present 
State Exam, Apathy Evaluation 
Scale, Neurobehavioural Rating 
Scale  
92% L L 
Multidisciplinary 
outpatient 
treatment for mTBI 
59 
151 32* (16-55) mild post-acute 
multicentre 
Number of days to sustainable 
RTW (1 year) 
RPQ, GOSE, Patient Global 
Impression (PGI, HADS 
RTW = 100% 
secondary 
outcomes = 
83% 
L L 
Telephone 
counselling 60 
365 29.3 (20-54) mild post-acute 
multicentre 
Pittsburgh Sleep Quality Index 
(PSQI) 
(6 and 12 months post-
intervention. Patients recruited 
within 24 months of return 
from service) 
RPQ, BSI-18, PTSD Checklist - 
Military Version (PCL-M), 
EuroQoL (pain question), 11-
point numerical rating scale 
(NRS-11) for pain, PHQ-9, SF-12, 
Sheehan Disability Scale, 
Alcohol use Disorders 
Identification Test (AUDIT-C) 
6 months = 
76% 
12 months = 
72% 
L U 
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 Supplementary Table 2: COAs by Type, Study Setting, and Frequency of Use  
 
Clinical Outcome Assessment  
Type  
of COA 
 
Acute 
Post-
Acute 
No. of 
studies 
1 Glasgow Outcome Scale (GOS) clinRO X 
 
21 
2 *Disability Rating Scale (DRS) clinRO X X 12 
3 *GOS - Extended (GOSE) structured interview  clinRO X X 11 
4 GOSE - questionnaire clinRO X 
 
10 
5 *SF-36 PRO X X 8 
6 *Trail Making Test (TMT) Part B perfO X X 7 
7 *Trail Making Test (TMT) Part A perfO X X 6 
8 *Controlled Oral Word Association Test (COWAT) perfO X X 6 
9 *Functional Independence Measure (FIM) clinRO X X 5 
10 *Selective Reminding Test (SRT) perfO X X 4 
11 *Galveston Orientation and Amnesia Test (GOAT) perfO X X 4 
12 Rivermead Post-Concussion Questionnaire (RPQ) PRO  X 4 
13 *EuroQol (EQ5D) PRO X X 3 
14 Clinical Global Impressions Scale  clinRO  X 3 
15 *Functional Status Examination (FSE) PRO X X 3 
16 Grooved Pegboard Test perfO X 
 
3 
17 Hopkins Verbal Learning Test (HVLT) perfO 
 
X 3 
18 Modified Oxford Handicap Scale (MOHS) clinRO X 
 
3 
19 Modified Perceived Quality of Life  (PQOL) PRO 
 
X 3 
20 *Paced Auditory Serial Addition Test (PASAT) perfO X X 3 
21 *Stroop Colour Word Test (Parts 1&2) perfO X X 3 
22 WAIS III Digit Span  perfO X 
 
3 
23 Beck Depression Inventory (BDI) II PRO 
 
X 2 
24 Brief Symptom Inventory - 18 (BSI-18) PRO 
 
X 2 
25 Community Integration Questionnaire (CIQ) PRO 
 
X 2 
26 California Verbal Learning Test (CVLT) PerfO X  2 
27 Diener Satisfaction with Life Scale PRO 
 
X 2 
 28 Finger Tapping Test perfO X 
 
2 
29 Head Injury Symptom Checklist  PRO 
 
X 2 
30 Kimura Memory for Designs Test perfO X 
 
2 
31 *Mini Mental State Exam (MMSE) perfO X X 2 
32 *Neurobehavioural Rating Scale  clinRO X X 2 
33 Patient Health Questionnaire (PHQ) depression PRO 
 
X 2 
34 *Rancho Los Amigos Scale clinRO X X 2 
35 Return to Work (RTW) clinRO 
 
X 2 
36 Rivermead Follow-up Questionnaire (RFQ) PRO 
 
X 2 
37 SF-12 PRO 
 
X 2 
38 *Symbol Digit Modalities Test  perfO X X 2 
39 WAIS III Processing Speed Index perfO X 
 
2 
40 WAIS III Letter-Number Sequencing perfO 
 
X 2 
41 Wisconsin Card Sorting Test (WCST) perfO 
 
X 2 
42 11-point numeric rating scale (NRS-11) PRO 
 
X 1 
43 Advocacy Behaviour Rating Scale (ABRS) clinRO 
 
X 1 
44 Alcohol Expectancy Questionnaire III PRO 
 
X 1 
45 Alcohol Use Disorders Identification Test (AUDIT-C) PRO 
 
X 1 
46 Apathy Evaluation Scale  PRO 
 
X 1 
47 Auditory Consonant Trigrams  perfO 
 
X 1 
48 Automatic Thoughts Questionnaire (ATQ) PRO 
 
X 1 
49 Barthel Index clinRO 
 
X 1 
50 Brief Symptom Inventory (BSI) PRO  X 1 
51 Brain Injury Community Rehabilitation Outcome-39 
(BICRO-39) 
PRO 
 
X 1 
52 Brief Visuospatial Memory Test perfO X 
 
1 
53 Cambridge Neuropsychological Test Automated 
Battery (CANTAB) Paired Associates Learning (PAL)  
perfO 
 
X 1 
54 CANTAB Rapid Visual Information Processing (RVP) perfO 
 
X 1 
55 CANTAB Reaction Time (RT) perfO 
 
X 1 
 56 CANTAB Spatial Working Memory (SWM) perfO 
 
X 1 
57 Category Fluency - Actions perfO X 
 
1 
58 Category Fluency - Animals perfO X 
 
1 
59 Choice Reaction Time perfO 
 
X 1 
60 Cognispeed Simple Reaction Time perfO 
 
X 1 
61 Cognispeed Subtraction Test perfO 
 
X 1 
62 Cognispeed Ten-Choice Reaction Time perfO 
 
X 1 
63 Cognispeed Vigilance Test perfO 
 
X 1 
64 Cognitive Abilities Screening Instrument (CASI) clinRO X 
 
1 
65 Color Trails 1 perfO X 
 
1 
66 Color Trails 2 perfO X 
 
1 
67 Coma Recovery Scale-Revised (CRS-R) clinRO 
 
X 1 
68 Dysfunctional Attitudes Scale (DAS) PRO 
 
X 1 
69 Environmental Reward Observation Scale (EROS) PRO 
 
X 1 
70 Epworth Sleepiness Scale (ESS) PRO 
 
X 1 
71 Finnish Traumatic Brain Injury Questionnaire (FITBIQ) PRO 
 
X 1 
72 Functional Assessment Measure (FAM) clinRO 
 
X 1 
73 Functional independence clinRO 
 
X 1 
74 General Health Questionnaire (GHQ) PRO 
 
X 1 
75 Halsted-Reitan Neuropsychological Impairment 
Index 
perfO 
 
X 1 
76 Hamilton Depression Rating Scale (HAMD-17) PRO 
 
X 1 
77 Hospital Anxiety and Depression Scale (HADS) PRO 
 
X 1 
78 Interest Checklist PRO 
 
X 1 
79 Job Satisfaction Checklist  PRO 
 
X 1 
80 Katz Adjustment Scale  PRO 
 
X 1 
81 Lexical Fluency perfO 
 
X 1 
82 Life satisfaction questionnaire (LiSat-11) PRO 
 
X 1 
82 Medical Outcomes Study 6-item Cognitive 
Functioning Scale 
PRO 
 
X 1 
 83 MINI  International Neuropsychiatric Interview clinRO 
 
X 1 
84 Multiple Sleep Latency Test (MSLT) perfO 
 
X 1 
85 Namewriting Test  perfO X 
 
1 
86 Neuropsychiatric Inventory (NPI-I) observer-rated ObsRO 
 
X 1 
87 Neuropsychiatric Inventory (NPI-I) participant-rated PRO 
 
X 1 
88 Occupational Gaps Questionnaire (OGQ) PRO 
 
X 1 
89 Paced Visual Serial Addition Task perfO 
 
X 1 
90 Participation with Recombined Tools - Objective 
(PART-O) 
PRO 
 
X 1 
91 Patient Global Impression (PGI) PRO 
 
X 1 
92 Patient Health Questionnaire (PHQ) panic/anxiety PRO 
 
X 1 
93 Patient Health Questionnaire-9 (PHQ-9) PRO  X 1 
94 Philadelphia Mindfulness Scale (PHLMS) PRO  X 1 
95 Pittsburgh Sleep Quality Index (PSQI) PRO 
 
X 1 
96 Post-Concussion Symptoms Questionnaire (PCSQ) PRO 
 
X 1 
97 Post-traumatic Checklist - Military Version (PCL-M) PRO 
 
X 1 
98 Present State Exam clinRO 
 
X 1 
99 Rankin Scale  clinRO X 
 
1 
100 Readiness to Change Questionnaire PRO 
 
X 1 
101 Rey-Osterrieth Complex Figure Test perfO X 
 
1 
102 Role Checklist PRO 
 
X 1 
103 Satisfaction with Depression Care  PRO 
 
X 1 
104 Seashore Rhythm Test perfO X 
 
1 
105 Semantic Fluency perfO 
 
X 1 
106 Sheehan Disability Scale PRO 
 
X 1 
107 Simple Reaction Time perfO 
 
X 1 
108 Spanish Verbal Learning Test perfO X 
 
1 
109 Symptom Checklist (SCL-20) PRO 
 
X 1 
110 Symptom Checklist (SCL-90) PRO 
 
X 1 
111 TBI Work Instability Scale  PRO 
 
X 1 
 112 Toronto Mindfulness Scale (TMS) PRO 
 
X 1 
113 Trahan Continuous Visual Memory Test perfO 
 
X 1 
114 WAIS III Digit Symbol perfO X 
 
1 
115 WAIS III Information and Vocabulary perfO 
 
X 1 
116 WAIS III Vocabulary  perfO 
 
X 1 
117 WAIS Matrix-Reasoning  perfO 
 
X 1 
118 WAIS performance intelligence quotient (PIQ) perfO X 
 
1 
119 WAIS Verbal Intelligence Quotient (VIQ) perfO X 
 
1 
120 WAISIII Symbol Search perfO X 
 
1 
121 Weschsler Abbreviated Scale of Intelligence (WASI) 
Full Scale IQ 
perfO X 
 
1 
122 WMS-R - General Memory perfO 
 
X 1 
123 WMS-R - Visual Reproduction perfO 
 
X 1 
124 WMS-R - Attention and Concentration Index perfO X 
 
1 
125 WMS-R - Logical Memory and Visual Reproduction  perfO X 
 
1 
126 Working Alliance Inventory-Short Form PRO 
 
X 1 
 
*COAs used in both acute and post-acute studies are marked with an asterisk         
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 3: RCT findings for different types of COA and study setting 
 
Type of COA and  
study setting 
 
Primary COA 
n(%) of RCTs* 
 
All COAs  
n(%) of RCTs** 
 
clinRO 
 
 
Acute 
 
30 (54%) 
 
27 (46%) 
 
Post-acute 
 
4 (7%) 
 
1 (2%) 
 
PRO 
 
 
Acute 
 
1 (2%) 
 
1 (2%) 
 
Post-acute 
 
8 (13%) 
 
8 (14%) 
 
PerfO 
 
 
Acute 
 
1 (2%) 
 
1 (2%) 
 
Post-acute 
 
1 (2%) 
 
0 (0%) 
 
obsRO 
 
 
Acute 
 
0 (0%) 
 
0 (0%) 
 
Post-acute 
 
0 (0%) 
 
0 (0%) 
 
More than one 
type of COA***  
 
Acute 
 
3 (5%) 
 
9 (15%) 
 
Post-acute 
 
7 (15%) 
 
11 (19%) 
 
                              TOTALS  
 
55 (100%) 
 
58 (100%) 
 
*Data are n(%) of the 55 studies using COAs as a primary outcome  
**Data are n(%) of the 58 studies using COAs in any capacity (i.e., as a primary outcome, 
secondary outcome, or as part of a composite outcome)  
***Includes all outcomes that comprised more than one type of COA (e.g., clinRO and PRO) 
 
  
 
